Value
6.3/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 2.6 |
| P/S | 9.1 |
| EV/EBITDA | 4.5 |
| Fwd P/E | 7.7 |
| PEG | 10.0 |
| Analyst target | 3.0 |
- ▸Forward P/E: 15.9x
- ▸PEG: 0.04
AMRX · Why this verdict
Why Amneal Pharmaceuticals (AMRX) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.5/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Amneal has delivered three consecutive earnings beats with an average positive surprise above 30%, but the stock sits within 0.2% of its resistance target with a risk/reward ratio of 0.03 — potential loss is roughly 34 times potential gain — making the setup a clear hold-only rather than an entry.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Four wholesale distributors account for 71% of revenue, meaning pricing pressure or the loss of any one of them could cause a disproportionate impact on the top line. Bear case | Annual filings show combined revenue share from the four named distributors declining below 60%, indicating meaningful customer diversification. | ↑Improving |
| CounterThese distribution channels dominate generic pharmaceutical logistics structurally; the concentration reflects how the market is built rather than a remediable strategic gap, and long-term supply agreements reduce near-term renegotiation risk. | ||
The company has beaten consensus estimates in three of the last four reported quarters, with the most recent delivering a 60% positive surprise, suggesting a pattern of under-promising and over-delivering against a modest analyst-consensus bar. Earnings | Beat rate remains at or above 75% over the next four reported quarters with average positive surprise above 10%. | ↑Improving |
| CounterWith only four analysts covering the name, the consensus benchmark is unreliably thin; beats against a sparse panel are a weaker signal of genuine outperformance than beats against deep, well-informed coverage. | ||
With an RSI of 85 and price sitting within 0.2% of the technical resistance ceiling, the stock is deeply overbought and has virtually no room for additional near-term gains without a meaningful pullback first. Momentum breakdown | RSI normalizes below 70 and price establishes a sustainable support base, creating a fresh entry window below resistance. | ↑Improving |
| CounterRising on-balance volume alongside the price advance signals genuine buyer conviction rather than speculative exhaustion; momentum can sustain elevated RSI readings longer than expected when accumulation is broad-based. | ||
Available upside to the price target is just 0.2% while downside is 6.8%, producing a risk/reward ratio of 0.03 — potential loss is roughly 34 times potential gain — a geometry that makes new exposure imprudent at current levels. Price targets | Setup becomes actionable only if the stock resets to a level where upside to the target exceeds downside by at least 1.5 times. | →Stable |
| CounterThe compressed price-to-earnings growth ratio and consistent earnings outperformance could attract an analyst target price upgrade, expanding available upside and improving the geometry without requiring a price pullback. | ||
Four wholesale distributors account for 71% of revenue, meaning pricing pressure or the loss of any one of them could cause a disproportionate impact on the top line.
↑ImprovingBear case
- Expectation
- Annual filings show combined revenue share from the four named distributors declining below 60%, indicating meaningful customer diversification.
CounterThese distribution channels dominate generic pharmaceutical logistics structurally; the concentration reflects how the market is built rather than a remediable strategic gap, and long-term supply agreements reduce near-term renegotiation risk.
The company has beaten consensus estimates in three of the last four reported quarters, with the most recent delivering a 60% positive surprise, suggesting a pattern of under-promising and over-delivering against a modest analyst-consensus bar.
↑ImprovingEarnings
- Expectation
- Beat rate remains at or above 75% over the next four reported quarters with average positive surprise above 10%.
CounterWith only four analysts covering the name, the consensus benchmark is unreliably thin; beats against a sparse panel are a weaker signal of genuine outperformance than beats against deep, well-informed coverage.
With an RSI of 85 and price sitting within 0.2% of the technical resistance ceiling, the stock is deeply overbought and has virtually no room for additional near-term gains without a meaningful pullback first.
↑ImprovingMomentum breakdown
- Expectation
- RSI normalizes below 70 and price establishes a sustainable support base, creating a fresh entry window below resistance.
CounterRising on-balance volume alongside the price advance signals genuine buyer conviction rather than speculative exhaustion; momentum can sustain elevated RSI readings longer than expected when accumulation is broad-based.
Available upside to the price target is just 0.2% while downside is 6.8%, producing a risk/reward ratio of 0.03 — potential loss is roughly 34 times potential gain — a geometry that makes new exposure imprudent at current levels.
→StablePrice targets
- Expectation
- Setup becomes actionable only if the stock resets to a level where upside to the target exceeds downside by at least 1.5 times.
CounterThe compressed price-to-earnings growth ratio and consistent earnings outperformance could attract an analyst target price upgrade, expanding available upside and improving the geometry without requiring a price pullback.
Per-dimension breakdown
Quality
5.9/10data confidence 100%| Component | Sub-score |
|---|---|
| ROA | 5.6 |
| Gross margin | 3.8 |
| Op margin | 7.8 |
| Net margin | 2.0 |
| Current ratio | 8.4 |
| FCF quality | 6.2 |
| Moat | 4.6 |
| Piotroski F | 8.9 |
- ▸No competitive moat
- ▸Strong Piotroski F-Score: 8/9
Growth
3.5/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 3.5 |
Momentum
6.0/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.5 |
| MACD | 2.8 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 2.7 |
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
6.7/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 7.5 |
| Analyst rating | 7.1 |
| Price target | 5.3 |
- ▸LLM news sentiment: +0.50 (n=2)
- ▸Light analyst coverage (4.0) — signal dampened
Insider
7.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸Insider selling (low materiality) — $450,558 (0.008% of mkt cap)
- ▸Institutions accumulating
Peer rank
3.4/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 4.2 |
| quality rank | 5.1 |
| growth rank | 4.4 |
Technical
4.0/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.7 |
| support resistance | 2.0 |
| 52w position | 9.4 |
Risk (lower is worse)
5.3/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 8.2 |
| days to cover | 7.5 |
| volatility | 4.7 |
| beta | 5.9 |
| debt equity | 0.0 |
| news risk | 5.5 |
- ▸Concentration risks: 1 HIGH, 1 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
7.2/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
| news activity | 6.0 |
- ▸Strong earnings: 3B/0M
- ▸Earnings in 9 days
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position.
Engine technical detail
verdict_path:
L4:PATH_F_SELLPassed (6)
- MOMENTUM:6.0>=5.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-1.1=NEGATIVE
Warning (1)
- EARNINGS_PROXIMITY:9d<=14d (soft)
Reward-to-Risk
-1.10
Upside
-13.1%
Downside
11.9%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeCatalyst-Driven — Earnings in 9d with 3/4 beat streak
SuitabilityModerate — Balanced profile
Investment implication
The F-path SELL output reflects an overall score of 4.0 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Insider at 7.3) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( ASYMMETRY:-1.1=NEGATIVE) reinforce the read. Current asymmetry R:R is -1.10 — supplementary context, not the trigger for this path.
The strongest dimensions are Insider at 7.3, Catalyst at 7.2, and Sentiment at 6.7; the weakest are Peer rank at 3.4, Growth at 3.5, and Technical at 4.0. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of -1.10 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Earnings Beat Discipline
Trip ifEPS surprise falls below 0% for 2 consecutive reported quarters.
- P2Overbought At Resistance
Trip ifPrice closes more than 5% above the $16.28 resistance level and holds there for 3 consecutive sessions, invalidating the overbought-at-ceiling reading.
- P3Distributor Concentration Risk
Trip ifRevenue share from the four major distributors falls below 55% in a subsequent annual filing.
- P4Unfavorable Risk Reward Geometry
Trip ifUpside to the take-profit target expands above 10% while downside remains below 8%, bringing the reward-to-risk ratio above 1.25.